JP2022515144A5 - - Google Patents

Info

Publication number
JP2022515144A5
JP2022515144A5 JP2021535618A JP2021535618A JP2022515144A5 JP 2022515144 A5 JP2022515144 A5 JP 2022515144A5 JP 2021535618 A JP2021535618 A JP 2021535618A JP 2021535618 A JP2021535618 A JP 2021535618A JP 2022515144 A5 JP2022515144 A5 JP 2022515144A5
Authority
JP
Japan
Prior art keywords
dnts
population
approximately
days
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021535618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515144A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2019/051866 external-priority patent/WO2020124248A1/en
Publication of JP2022515144A publication Critical patent/JP2022515144A/ja
Publication of JP2022515144A5 publication Critical patent/JP2022515144A5/ja
Pending legal-status Critical Current

Links

JP2021535618A 2018-12-19 2019-12-19 オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用 Pending JP2022515144A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862782005P 2018-12-19 2018-12-19
US62/782,005 2018-12-19
PCT/CA2019/051866 WO2020124248A1 (en) 2018-12-19 2019-12-19 Production and therapeutic use of off-the-shelf double negative t cells

Publications (2)

Publication Number Publication Date
JP2022515144A JP2022515144A (ja) 2022-02-17
JP2022515144A5 true JP2022515144A5 (https=) 2022-12-20

Family

ID=71099979

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021535618A Pending JP2022515144A (ja) 2018-12-19 2019-12-19 オフザシェルフのダブルネガティブｔ細胞の産生および治療的使用

Country Status (6)

Country Link
US (2) US20220073877A1 (https=)
EP (1) EP3898950A4 (https=)
JP (1) JP2022515144A (https=)
CN (1) CN113454209A (https=)
CA (1) CA3123467A1 (https=)
WO (1) WO2020124248A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102394512B1 (ko) * 2021-05-03 2022-05-06 주식회사 지씨셀 동결 활성화 림프구 및 이의 제조 방법
EP4458378A4 (en) * 2021-12-30 2025-07-09 Chongqing Prec Biotech Co Ltd TECHNIQUE FOR PREPARING A UNIVERSAL CAR-T CELL, AND APPLICATION OF A UNIVERSAL CAR-T CELL
JP2025517437A (ja) * 2022-05-20 2025-06-05 武田薬品工業株式会社 操作された免疫細胞を産生する方法
CN117860782B (zh) * 2024-03-11 2024-05-28 中国康复科学所(中国残联残疾预防与控制研究中心) 双阴性t细胞在制备治疗脊髓损伤的药物中的用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953576B2 (en) * 2000-08-21 2005-10-11 University Health Network Method of modulating tumor immunity
CN101313061B (zh) * 2005-11-18 2013-05-15 大学健康网络 扩增双阴性t细胞的方法
RU2739770C2 (ru) * 2014-06-11 2020-12-28 полибайосепт ГмбХ Экспансия лимфоцитов с использованием композиции цитокинов для активной клеточной иммунотерапии
CN104109653B (zh) * 2014-06-12 2017-06-13 浙江瑞顺生物技术有限公司 利用无动物血清培养体系大规模扩增人外周血dnt细胞的方法
JP6802150B2 (ja) * 2014-08-15 2020-12-16 ユニバーシティー ヘルス ネットワーク がん治療のための免疫療法
US11534460B2 (en) * 2015-05-11 2022-12-27 University Health Network Method for expansion of double negative regulatory T cells
US10201572B2 (en) * 2015-09-15 2019-02-12 University Health Network Combination therapy with double negative T-cells
CN105483083B (zh) * 2016-01-20 2018-10-23 北京医明佳和生物科技有限公司 双阴性t细胞的转化扩增方法
WO2019145956A1 (en) * 2018-01-25 2019-08-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods for improved immunotherapy

Similar Documents

Publication Publication Date Title
JP7788486B2 (ja) 治療的用途のためのフコシル化細胞の製造
US11517592B1 (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
Safinia et al. Regulatory T cells: serious contenders in the promise for immunological tolerance in transplantation
Berg et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells
Childs et al. Bringing natural killer cells to the clinic: ex vivo manipulation
Wang et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale
Min et al. Optimization of large-scale expansion and cryopreservation of human natural killer cells for anti-tumor therapy
US9114100B2 (en) Methods of treatment using ex vivo expansion of cord blood T cells
JP2022515144A5 (https=)
JP6073417B2 (ja) 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
JP2023505102A (ja) ナチュラルキラー細胞を製造する方法およびその組成物
CN107002039A (zh) 使用t细胞用于培养自然杀伤细胞的方法
US20250235482A1 (en) Production and therapeutic use of off-the-shelf double negative t cells
Bremm et al. Improving clinical manufacturing of IL-15 activated cytokine-induced killer (CIK) cells
KR20160066837A (ko) 안정성 높은 자연살해세포의 효율적인 제조방법
Davis et al. Interleukin-7 permits Th1/Tc1 maturation and promotes ex vivo expansion of cord blood T cells: a critical step toward adoptive immunotherapy after cord blood transplantation
Schlieer et al. Tregs: application for solid-organ transplantation
Moustaki et al. Effect of the simultaneous administration of glucocorticoids and IL-15 on human NK cell phenotype, proliferation and function
Okas et al. Clinical expansion of cord blood-derived T cells for use as donor lymphocyte infusion after cord blood transplantation
WO2023200929A1 (en) Tumor-infiltrating lymphocyte (til) compositions and uses thereof
Kellner et al. Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen
HK40079211A (en) Method of producing natural killer cells and compositions thereof
ROXANA et al. CRYOPRESERVATION OF NATURAL KILLER CELLS
Cho et al. Selective expansion of natural killer cells from peripheral blood mononuclear cells by K562 cell line and IL-2